Skip to main content
Terug
GNTLF logo

Genetic Technologies Limited

Datakwaliteit: 100%
Overbought
GNTLF
OTC Healthcare Medical - Diagnostics & Research
€ 1,00
€ 0,00 (0,00%)
Marktkapitalisatie: 1,34B
Dagbereik
€ 1,00 € 1,00
52-Weeksbereik
€ 1,00 € 1,00
Volume
100
50D / 200D Gem.
€ 1,00 / € 1,00
Vorige Slotkoers
€ 1,00

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E -111,1 0,4
P/B 729,6 2,9
ROE % -185,0 3,7
Net Margin % -124,2 3,9
Rev Growth 5Y % 84,3 10,0
D/E 0,5 0,2

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2026 € 0,00
€ 0,00 – € 0,00
20 M 0

Belangrijkste Punten

Revenue grew 84,33% annually over 5 years — strong growth
Debt/Equity of 0,48 — conservative balance sheet
Negative free cash flow of -9,71M
PEG of 0,05 suggests growth is underpriced
Revenue growth is decelerating — 1Y growth trails 5Y average by 90,85%
Capital efficient — spends only 0,34% of revenue on capex

Groei

Revenue Growth (5Y)
84,33%
Revenue (1Y)-6,52%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-184,98%
ROIC-338,47%
Net Margin-124,24%
Op. Margin-126,23%

Veiligheid

Debt / Equity
0,48
Current Ratio0,88
Interest Coverage-236,53

Waardering

P/E Ratio
-111,13
P/B Ratio729,57
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -6,52% Revenue Growth (3Y) 2,44%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 84,33% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 9,67M Net Income (TTM) -12,02M
ROE -184,98% ROA -194,25%
Gross Margin 40,37% Operating Margin -126,23%
Net Margin -124,24% Free Cash Flow (TTM) -9,71M
ROIC -338,47% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,48 Current Ratio 0,88
Interest Coverage -236,53 Dividend Yield 0,00%
Valuation
P/E Ratio -111,13 P/B Ratio 729,57
P/S Ratio 138,06 PEG Ratio 0,05
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 1,34B Enterprise Value 1,34B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 9,67M 10,35M 9,22M 1,33M 837.865,0
Net Income -12,02M -11,75M -7,13M -7,08M -6,29M
EPS (Diluted) -0,09 -0,12 -0,08 -0,08 -0,15
Gross Profit 3,90M 6,01M 6,47M -240.473,0 736.432,0
Operating Income -12,21M -6,07M -4,81M -5,80M -5,94M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 6,19M 14,86M 20,80M 22,97M 15,63M
Total Liabilities 4,36M 3,69M 4,37M 1,44M 1,64M
Shareholders' Equity 1,83M 11,16M 16,43M 21,53M 13,02M
Total Debt 875.189,0 532.846,0 652.526,0 204.038,0 481.788,0
Cash & Equivalents 1,02M 7,85M 11,73M 20,90M 14,21M
Current Assets 3,70M 10,50M 14,72M 22,24M 15,19M
Current Liabilities 4,20M 3,31M 3,81M 1,41M 1,40M